Treatment Landscape in HR+, HER2- MBC

 

Total Health
Avatar

HR+ mBC: Optimizing Endocrine Therapy

By Total Health FEATURING Joyce O'Shaughnessy
By Total Health FEATURING Joyce O'Shaughnessy
880 views
March 30, 2023
1 Comment
Login to view comments. Click here to Login
Treatment Landscape in HR+, HER2- MBC
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
08:40
PrecisCa

Managing Common Toxicities From CDK4/6i

Feat. E. Shonkwiler
08:51
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Effects of Ovarian Ablation or Suppressio…

Feat. R. Gray
05:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Results of the Phase 3 SAFE Trial -…

Feat. C. Becherini, L. Livi
06:55
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Comparative OS of Pts in Trials of CKD4/6…

Feat. C. Kappel
13:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Subgroup Analysis of the RIGHT Choice Tri…

Feat. N. El Saghir
19:21
Abirami Sivapiragasam

Sequencing Treatment Options for HR+ mBC

12:44
SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the Randomized Phase II RIGHT Choice…

Feat. Y. Lu
19:12
Penn Medicine Abramson Cancer Center

Updates in HR+ mBC

Feat. I. Makhlin
17:31
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Case Studies Discussion of Patients with HR+/HER2- mBC

Feat. N. Hunter
26:03
Total Health

HR+ mBC: Optimizing Endocrine Therapy

Feat. J. O'Shaughnessy
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
19:02
Denise Yardley

Phase III Pooled MONALEESA Safety & Efficacy Data in HR+/HER2- m…

10:43
Ahmad Awada

Recent Development in the Treatment of HR+/HER2- mBC

22:17
RWJBarnabas Health Rutgers Cancer Institute of New Jersey

Administration, Safety, and Dosing of Ribociclib for ER+/HER2- mBC

Feat. J. Lauria
08:31
Neelam Desai

Comparing the Efficacy Data of CDK4/6i in HR+/HER2- mBC

13:35
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The RIGHT Choice Trial - 1L Ribociclib + E…

Feat. H. Azim
12:08
West Cancer Center

Patient Selection for CDK4/6i in HR+/HER2- Advanced BC

Feat. G. Vidal